Anticoagulation and antiplatelet strategies used in Sweden in patients with myocardial infarction and concomitant atrial fibrillation: nationwide cohort study.

ABSTRACT:

Background

Optimal antithrombotic therapy and its duration, whether triple therapy with dual antiplatelets plus oral anticoagulant (OAC), or dual antithrombotic therapy with an antiplatelet plus OAC, is uncertain for patients with myocardial infarction (MI) and atrial fibrillation (AF).

Methods

Patients registered in SWEDEHEART (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) for their first MI between 2011 and 2021 with a history or new-onset AF were included (n=26 574). Linkage between SWEDEHEART and Swedish administrative health databases was performed, and pseudonymised data analysed.

Results

Over time, OAC use at discharge after MI tripled from 27% in 2011 to 77% in 2021, wit

SUBMITTER: Aulin J 

PROVIDER: S-EPMC12406944 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature